Organisation paid for research Program year 2025 Source: CMS Open Payments

Carolina Research Center

Neither a doctor nor a teaching hospital

Research payments

$244,943

21 payments

Through program year 2025, Carolina Research Center is reported as receiving $244,943 in research payments, across 21 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $31,055 4
2024 Research $12,160 2
2022 Research $13,866 2
2021 Research $147,053 9
2020 Research $7,712 1
2019 Research $33,096 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $127,151 6 payments
  2. Biohaven Pharmaceuticals, Inc. $53,058 7 payments
  3. GlaxoSmithKline, LLC. $33,412 6 payments
  4. AstraZeneca Pharmaceuticals LP $31,308 1 payment
  5. Celgene Corporation $14 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $96,777 2 payments
  2. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $45,346 6 payments
  3. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $31,308 1 payment
  4. A Two-Part Phase 1 Randomized, Double-Blind, Placebo-Controlled Study $19,477 3 payments
  5. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $12,580 1 payment
  6. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $12,160 2 payments
  7. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $11,012 2 payments
  8. A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $7,712 1 payment
  9. A 12-Week Randomized, Participant-And Investigator-Blinded, Placebo-Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled Csj117 in Adults With Chronic Obstructive Pulmonary Disease (COPD) $6,782 1 payment
  10. A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $1,774 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record